A HIGHER ASPIRATION IN CANCER THERAPY.

We are developing targeted, patient-specific therapies for some of the hardest-to-treat cancers.  We aren’t satisfied with limited lifetime extensions.  Our unique cancer-targeting agents and treatment approach offer the potential for truly curative responses in historically terminal diseases.

OUR PUBLICATIONS

Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs
View more
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
View more
177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
View more
Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer
View more
Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
View more
In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predict Partitioning and Pharmacokinetics
View more
Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs
View more
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
View more
177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
View more
Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer
View more
Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
View more
In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predict Partitioning and Pharmacokinetics
View more

OUR LEADERSHIP
TEAM

Evan Sengbusch, PhD, MBA
CEO, Director
Reinier Hernandez, PhD
CTO
David Casimir, PhD, JD
Director, Chairman
Jon Ohrn, JD
Director
Howard Bailey, MD
Director
Evan Sengbusch, PhD, MBA
CEO, Director
Reinier Hernandez, PhD
CTO
David Casimir, PhD, JD
Director, Chairman
Jon Ohrn, JD
Director
Howard Bailey, MD
Director

OUR ADVISORS

Jamey Weichert, PhD
Chief Science Advisor
View bio
Jamey Weichert, PhD

Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.

Zach Morris MD, PhD
Chief Medical Advisor
View bio
Zach Morris MD, PhD

Zach is an associate professor and  chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.

Mike Tweedle, PhD
Advisory Board Member
View bio
Mike Tweedle, PhD

Mike is the professor, chair in cancer imaging, and a member of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center. His research there focuses on new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging. Mike developed ProHance, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. He also invented the first catalysts for the production of technetium radiopharmaceutical kits for cardiac imaging and created some of the earliest targeted molecular imaging agents from monoclonal antibodies. He is an inventor on over 35 patents and has co-authored more than 100 peer reviewed publications. Before coming to the OSUCCC, he served as president and CEO of Bracco Research USA and as the head of the diagnostics R&D division of Bristol Meyers Squibb.

Norman LaFrance, MD
Advisory Board Member
View bio
Norman LaFrance, MD

Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.

Wolfgang Tome, PhD
Advisory Board Member
View bio
Wolfgang Tome, PhD

Wolfgang is a professor in the departments of radiation oncology and neurology and the director of medical physics for the Institute for Onco-Physics at the Albert Einstein College of Medicine. His research interests include whole brain radiotherapy, stereotactic radiosurgery, MR-guided radiotherapy, decision support systems for adaptive radiation therapy, and functional imaging for risk-adaptive radiotherapy and tumor response assessment. He is more specifically focused on hippocampal avoidance and preservation of neurocognitive function in patients with inoperable brain tumors requiring palliative radiation. Wolfgang has a prolific peer-reviewed publication record and is the inventor on multiple patents for technologies focused in cancer imaging and treatment.

Kevin Brooks, MBA
Advisory Board Member
View bio
Kevin Brooks, MBA

Kevin has been a senior executive in the radiopharmaceutical industry for over 30 years with extensive product development and commercialization experience.  He most recently served as president at Nordion, a Sotera Health Company.  Prior to that, he was senior VP of marketing and sales for Nordion’s medical isotope business, including PET, SPECT, and therapeutic isotopes.  Earlier in his career he held leadership roles in business development, strategy, and marketing at Jubilant Draximage, GE Healthcare’s Cardiovascular Radiopharmaceuticals division, and Bracco Diagnostics’ nuclear medicine business.

Jamey Weichert, PhD
Chief Science Advisor
View bio
Jamey Weichert, PhD

Jamey is a co-founder of Archeus and a professor of radiology at the University of Wisconsin with affiliate appointments in medical physics and pharmaceutics. He has a PhD in Medicinal Chemistry from the University of Michigan. He established UW-Madison’s Small Animal Imaging and Radiotherapy Facility and currently serves as its faculty director. Jamey is the lead scientist responsible for developing several of Archeus’ pipeline cancer imaging and therapy agents. He currently oversees a large research group that is responsible for much of the preclinical work underlying Archeus’ technologies, with focus areas in cancer-targeted molecular contrast agents, PET and CT imaging, and targeted radionuclide therapy. He has over 80 peer reviewed publications, is the co-inventor on more than 50 patents, and is the principal investigator on several major NIH grant programs. At Archeus, Jamey is responsible for scientific oversight of all preclinical research and pipeline development activities.

Zach Morris MD, PhD
Chief Medical Advisor
View bio
Zach Morris MD, PhD

Zach is an associate professor and  chair of the Department of Human Oncology at the University of Wisconsin. He is a Rhodes Scholar and completed an MD/PhD at Harvard’s Biological and Biomedical Sciences Program. Zach is a practicing physician with a clinical focus on the treatment of patients with melanoma and soft tissue sarcomas. He leads an independent translational research lab at UW-Madison focused on novel treatment approaches utilizing targeted radioisotope therapies. He is an active member of several professional societies and has an extensive publication record. He is actively involved in preclinical research with Archeus’ cancer-targeting agents and is leading the design and oversight of the company’s planned clinical trials.

Mike Tweedle, PhD
Advisory Board Member
View bio
Mike Tweedle, PhD

Mike is the professor, chair in cancer imaging, and a member of the Translational Therapeutics Program at the Ohio State University Comprehensive Cancer Center. His research there focuses on new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging. Mike developed ProHance, the first nonionic macrocyclic MRI agent, which has been used in more than 50 million patients. He also invented the first catalysts for the production of technetium radiopharmaceutical kits for cardiac imaging and created some of the earliest targeted molecular imaging agents from monoclonal antibodies. He is an inventor on over 35 patents and has co-authored more than 100 peer reviewed publications. Before coming to the OSUCCC, he served as president and CEO of Bracco Research USA and as the head of the diagnostics R&D division of Bristol Meyers Squibb.

Norman LaFrance, MD
Advisory Board Member
View bio
Norman LaFrance, MD

Norman is the chief medical officer and senior VP at Plus Therapeutics. He was previously chief medical officer and Senior VP at Jubilant Pharma, responsible for all pharma medical & regulatory affairs activities. Prior to Jubilant, he served as global chief medical officer at IBA Molecular and as senior VP, clinical development and chief medical officer at Molecular Insight Pharmaceuticals. Prior to industry, Norman practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is double board certified with fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the US along with active professional society memberships.

Wolfgang Tome, PhD
Advisory Board Member
View bio
Wolfgang Tome, PhD

Wolfgang is a professor in the departments of radiation oncology and neurology and the director of medical physics for the Institute for Onco-Physics at the Albert Einstein College of Medicine. His research interests include whole brain radiotherapy, stereotactic radiosurgery, MR-guided radiotherapy, decision support systems for adaptive radiation therapy, and functional imaging for risk-adaptive radiotherapy and tumor response assessment. He is more specifically focused on hippocampal avoidance and preservation of neurocognitive function in patients with inoperable brain tumors requiring palliative radiation. Wolfgang has a prolific peer-reviewed publication record and is the inventor on multiple patents for technologies focused in cancer imaging and treatment.

Kevin Brooks, MBA
Advisory Board Member
View bio
Kevin Brooks, MBA

Kevin has been a senior executive in the radiopharmaceutical industry for over 30 years with extensive product development and commercialization experience.  He most recently served as president at Nordion, a Sotera Health Company.  Prior to that, he was senior VP of marketing and sales for Nordion’s medical isotope business, including PET, SPECT, and therapeutic isotopes.  Earlier in his career he held leadership roles in business development, strategy, and marketing at Jubilant Draximage, GE Healthcare’s Cardiovascular Radiopharmaceuticals division, and Bracco Diagnostics’ nuclear medicine business.

WANT TO
GET IN TOUCH?

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

WANT TO
GET IN TOUCH?

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.